These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 32046074)

  • 41. Cardiovascular disease in patients with diabetic nephropathy.
    Aso Y
    Curr Mol Med; 2008 Sep; 8(6):533-43. PubMed ID: 18781960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment".
    Ruiz-Ortega M; Rodrigues-Diez RR; Lavoz C; Rayego-Mateos S
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32192024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene therapy, a targeted treatment for diabetic nephropathy.
    Lin X; Tao L; Tang D
    Curr Med Chem; 2013; 20(30):3774-84. PubMed ID: 23895680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terpene glycoside component from Moutan Cortex ameliorates diabetic nephropathy by regulating endoplasmic reticulum stress-related inflammatory responses.
    Chen J; Hou XF; Wang G; Zhong QX; Liu Y; Qiu HH; Yang N; Gu JF; Wang CF; Zhang L; Song J; Huang LQ; Jia XB; Zhang MH; Feng L
    J Ethnopharmacol; 2016 Dec; 193():433-444. PubMed ID: 27664441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.
    Donate-Correa J; Tagua VG; Ferri C; Martín-Núñez E; Hernández-Carballo C; Ureña-Torres P; Ruiz-Ortega M; Ortiz A; Mora-Fernández C; Navarro-González JF
    J Clin Med; 2019 Feb; 8(3):. PubMed ID: 30818852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of IL-18 in type 1 diabetic nephropathy: The problem and future treatment.
    Elsherbiny NM; Al-Gayyar MM
    Cytokine; 2016 May; 81():15-22. PubMed ID: 26836949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy.
    Luis-Rodríguez D; Martínez-Castelao A; Górriz JL; De-Álvaro F; Navarro-González JF
    World J Diabetes; 2012 Jan; 3(1):7-18. PubMed ID: 22253941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inflammation and the pathogenesis of diabetic nephropathy.
    Wada J; Makino H
    Clin Sci (Lond); 2013 Feb; 124(3):139-52. PubMed ID: 23075333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.
    Arora MK; Singh UK
    Vascul Pharmacol; 2013 Apr; 58(4):259-71. PubMed ID: 23313806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diabetic nephropathy: An update on pathogenesis and drug development.
    A/L B Vasanth Rao VR; Tan SH; Candasamy M; Bhattamisra SK
    Diabetes Metab Syndr; 2019; 13(1):754-762. PubMed ID: 30641802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress.
    Mou Z; Feng Z; Xu Z; Zhuang F; Zheng X; Li X; Qian J; Liang G
    Biochem Biophys Res Commun; 2019 Jan; 508(1):243-249. PubMed ID: 30477745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proteomics and diabetic nephropathy.
    Merchant ML; Klein JB
    Curr Diab Rep; 2005 Dec; 5(6):464-9. PubMed ID: 16316599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy.
    Navarro JF; Mora C
    ScientificWorldJournal; 2006 Aug; 6():908-17. PubMed ID: 16906324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tonicity-Responsive Enhancer-Binding Protein Mediates Hyperglycemia-Induced Inflammation and Vascular and Renal Injury.
    Choi SY; Lim SW; Salimi S; Yoo EJ; Lee-Kwon W; Lee HH; Lee JH; Mitchell BD; Sanada S; Parsa A; Kwon HM
    J Am Soc Nephrol; 2018 Feb; 29(2):492-504. PubMed ID: 29158465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy.
    Pappa M; Dounousi E; Duni A; Katopodis K
    Int Urol Nephrol; 2015 Aug; 47(8):1365-72. PubMed ID: 26017902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy.
    Qiu YY; Tang LQ
    Pharmacol Res; 2016 Dec; 114():251-264. PubMed ID: 27826011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Advances in the role of autoantibodies in diabetic nephropathy: Review].
    Zhou Z; Luo R; Wan Z; Kuang H; Lyu J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Feb; 36(2):175-179. PubMed ID: 32314716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy.
    Yang S; Han Y; Liu J; Song P; Xu X; Zhao L; Hu C; Xiao L; Liu F; Zhang H; Sun L
    Curr Med Chem; 2017; 24(29):3185-3202. PubMed ID: 28486920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histological changes of kidney in diabetic nephropathy.
    Pourghasem M; Shafi H; Babazadeh Z
    Caspian J Intern Med; 2015; 6(3):120-7. PubMed ID: 26644877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.